Youngene Therapeutics announced today that its first study of YG1699 in patients with diabetes successfuly reachedits primary endpoint. The data will be presented at the European Association for the Study of Diabetes (EASD)

conference in September, 2022.

YG1699 is a dual inhibitor of SGLT1 and SGLT2.This Phase ll rial was a randomized, double-blind, crossover studycomparing YG1699 to dapaglifiozin (a selective SGLT2 inhibitor) in subjects with Type 1 diabetes mellitus. The primaryendpoint compared YG1699 to dapaglifiozin in post-prandial glucose control during a mixed meal tolerance test. YG1699demonstrated significantly better post-prandialglucose control than dapaglifiozin.Both treatments were well tolerated.

Pablo Lapuerta M.D. Chief Medical Officer lt was important to examine whether YG1699 could offer patients efficacy beyond that of a leading|sGLT2 inhibitor. In this study，YG1699 provided better glycemic control with a differentiated; mechanism of action.

About Youngene Therapeutics:

Youngene Therapeutics is a clinical stage pharmaceutical company with a primary focus on metabolic and cardiovasculardiseases. In addition to this Phase 2 study,YG1699 completed a Phase 1 study in the USA and is currently beingevaluated in a pharmacokinetic bridging study in healthy volunteers in China.